Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS: Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease
NCT00427921Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jan 2007
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by Abbott Laboratories. Primary endpoints: Mean Extent of Exposure - Duration in Days up to 24 weeks, Total Number of Injections of Adalimumab up to 24 weeks and 1 more. Started Jan 2007; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00427921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427921.